PharmaShots | Incisive News in 3 Shots

Subscribe Now

anti-PD-1 antibody

NMPA- China Accepts NDA for BeiGene & Boehringer BioChina's Tislelizumab for the treatment of r/r cHL

NMPA- China Accepts NDA for BeiGene & Boehringer BioChina's Tislelizumab for the treatment of r/r cHL

September 4, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us